Roche Partners With Peptide Specialist Aileron For Five Targets
This article was originally published in The Pink Sheet Daily
A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.
You may also be interested in...
The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.
At Elsevier Business Intelligence's recent Therapeutic Area Partnerships conference, a roundtable of senior pharmaceutical executives and entrepreneurs weighed in on industry’s current funding challenges, how dealmaking defines a biotech’s ambitions and strategy, and pharma’s appetite for early-stage innovation.
Dutch biotech Lanthio Pharma has entered into an alliance with MorphoSys to develop its lantipeptide technology, with the German drug-discovery company also participating in Lanthio Pharma’s Series A funding round.